Pharmaceutical industry spring summit: Greece at the heart of pharmaceutical innovation
en.protothema.gr - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from en.protothema.gr Daily Mail and Mail on Sunday newspapers.
Regulus Therapeutics (RGLS) announces Simos Simeonidis resigns from board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ally Bridge Group: SIMOS SIMEONIDIS, PHD JOINS ALLY BRIDGE GROUP AS CO-CEO AND CO-CIO
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
NEW YORK, July 21, 2022 /PRNewswire/ Ally Bridge Group (the "Firm") is pleased to announce Simos Simeonidis, PhD joined the Firm as Co-Chief Executive Officer and Co-Chief Investment Officer based in New York. Dr. Simeonidis is also assuming the role of Portfolio Manager for Ally Bridge Group's public equity strategy. Ally Bridge Group is a global healthcare investment manager focused on high-impact life science innovation addressing unmet medical needs. The Firm manages both private equity vehicles and a long-biased public equity strategy with specialization across the medical technology, tools and diagnostics, biopharmaceuticals and digital health subsectors. Ally Bridge Group was founded in 2013 by Frank Yu and has offices in New York and Hong Kong. In a recent letter sent to investors, Mr. Yu explained Dr. Simeonidis will partner with him in leading firmwide strategic initiatives and achieving investment objectives. Mr. Yu will remain at the Firm as Founder, Co-Chief